




## Clinical Evidence for CytoSorb® Therapy in Liver


Name	Title	Aim	Number of patients	Type of study	Outcome
<a href="#">Ocskay et al., J Clin Med 2021; 10(21):5182</a>	Hemoadsorption in 'Liver Indication' - Analysis of 109 patients' data from the CytoSorb® international registry.	Analysis of 'liver indication' subgroup patients from the CytoSorb International Registry (total 1434 patients).	109	Registry	Baseline serum bilirubin levels were significantly reduced pre versus post CytoSorb® use.
<a href="#">Scharf et al., Sci Rep 2021; 11(1); 10190</a>	Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study.	Compare bilirubin removal by CytoSorb® with removal by ADVOS in patients with acute liver failure (various etiologies).	33	Case series	Both devices led to significant bilirubin removal & lower than expected mortality rates but only CytoSorb® use resulted in hemodynamic stabilization and was much easier to use.
<a href="#">Tomescu et al., Int J Artif Organs 2021; 44(8): 560-4</a>	Haemoadsorption by CytoSorb® in patients with acute liver failure: a case series.	Assess clinical effects of CytoSorb® in biochemical parameters in patients with acute liver failure. Patients treated with 3 consecutive 24 hrs sessions.	28	Case series	Suggest use of CytoSorb® as a therapeutic option for management of liver impairment providing biochemical control, aiding bridge to liver transplantation, or until spontaneous remission.
<a href="#">Dhokia et al., J of Intensive Care Soc 2019; 0(2): 174 - 181</a>	Novel use of CytoSorb® haemoadsorption to provide biochemical control in liver impairment.	Describe use of CytoSorb® in 2 patients with drug induced cholestasis and 1 patient with alcoholic hepatitis to remove bilirubin and bile acids.	3	Retrospective case series	In all cases there was a meaningful reduction in bilirubin and bile acids with improvement in clinical symptoms.





## Clinical Evidence for CytoSorb® Therapy in Liver

Name	Title	Aim	Number of patients	Type of study	Outcome
 <b>Buttner et al., Blood Purif 2017; 44(1): 30 - 31</b>	Application of hemoadsorption in a case of liver cirrhosis and alcohol-related steatohepatitis with preexisting hepatitis C infection.	Patient with chronic viral hepatitis C and long term chronic alcoholic cirrhosis where CytoSorb® was used to remove inflammation-triggering factors and liver toxins (bilirubin, bile acid, ammonia).	1	Case report	Pre and post adsorber measurements confirmed efficient removal of ammonia, bilirubin and bile acids. CytoSorb® worked extremely well and effectively as a liver support.



### CytoSorbents Europe GmbH

Müggelseedamm 131  
12587 Berlin | Germany

T +49 30 65 49 91 45  
F +49 30 65 49 91 46  
support@cytosorbents.com

Register for the literature newsletter

Visit our literature database for an overview of all references



www.cytosorb.com

The clinical and preclinical data and results obtained with the CytoSorb® adsorber are not transferable to other products. CytoSorb® should only be administered by health care professionals, properly trained in administration of extracorporeal therapies. The statements here represent the personal opinions and views of the author(s) only and do not necessarily reflect accepted medical knowledge in general or indications covered by the intended use of CytoSorb®. CytoSorb® and CytoSorbents are trademarks of the CytoSorbents Corporation, USA. © Copyright 2022, CytoSorbents Europe GmbH. All rights reserved. B1297R01ENG2022